Neoplasma Vol.67, No.6, p.1384–1390, 2020
|
Title: Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib |
Author: Y. CHENG, F. C. DU, F. Q. FANG, Z. J. DUAN, W. LEI, K. G. SHI |
|
Abstract: The clinical efficiency and adverse reactions of anlotinib in metastatic colorectal cancer (mCRC) as a third-line treatment compared with chemotherapy and regorafenib or fruquintinib was explored in this study. Clinical data from 105 mCRC patients who failed at least two lines of chemotherapy were collected. The patients were divided into three groups based on their third-line therapeutic regimen: third-line chemotherapy only (group A); anlotinib (group B); and fruquintinib or regorafenib (group C). The result showed that the ORR and DCR of group B (14.29%, 85.71%) were higher than those of group A (0%, 40.00%). The ORRs of group B and group C were 14.29% and 20.00%, respectively. Group B and group C had the same DCR, 85.71%. The mean PFS values of group B (3.46 months) and group C (3.33 months) were longer than that of group A (2.25 months) (χ2 = 84.255, P intestinal reaction were more common in group A than in group B and group C (P apy and similar to regorafenib or fruquintinib. The associated adverse reactions are tolerable.
|
|
Keywords: metastatic colorectal cancer; anlotinib; chemotherapy; fruquintinib; regorafenib |
|
Published online: 13-Jul-2020
|
Year: 2020, Volume: 67, Issue: 6 |
Page From: 1384, Page To: 1390 |
doi:10.4149/neo_2020_191125N1212
|
|
download file |
|
|
|
|